Third, although this study represents the largest cohort evaluating TEs in advanced lung adenocarcinoma with RET fusions, the cohort size remains relatively small due to the rarity of RET fusions in NSCLC, limiting the ability to detect significant differences among driver genes. The gene discussed is RET; the disease is non-small cell lung carcinoma.